ArticleThe American journal of tropical medicine and hygiene2026
Baseline Anti-Dengue IgG Seroprevalence in a Pediatric Brazilian Population Before TAK-003 Vaccination.
Article in The American journal of tropical medicine and hygiene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue remains a major public health challenge in Brazil, with recurrent outbreaks placing a strain on healthcare systems. The TAK-003 vaccine offers a promising control strategy, particularly for children. This cross-sectional study evaluated the seroprevalence of anti-dengue IgG in 643 children and adolescents aged 4-16 years in Dourados, Brazil, before being administered the TAK-003 vaccine. Capillary blood samples were collected on filter paper and analyzed using ELISA; sociodemographic data were obtained through questionnaires. Overall, 20.5% of participants were seropositive. Seropositivity increased with age, with 27.7% among those aged 13-16 years testing positive compared with 13.4% among children aged 4-8 years. Male sex was associated with lower IgG levels. The age-related increase in anti-dengue IgG seroprevalence reflects cumulative exposure to the virus during childhood and adolescence, highlighting the need for immunization strategies tailored to age. These findings emphasize the importance of baseline anti-dengue IgG seroprevalence data to guide vaccination, assess effectiveness, and monitor antibody-dependent enhancement risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.